Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 112.90% | 42.15% | 64.96% | -10.99% | -24.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 112.90% | 42.15% | 64.96% | -10.99% | -24.44% |
| Cost of Revenue | 119.87% | 67.32% | 14.98% | -56.80% | 31.90% |
| Gross Profit | 107.28% | 30.87% | 117.30% | 704.12% | -43.84% |
| SG&A Expenses | 76.67% | 89.25% | 150.79% | -5.28% | 7.93% |
| Depreciation & Amortization | -68.72% | -65.11% | -43.80% | -26.77% | 34.66% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.47% | 62.65% | 85.07% | 0.13% | 21.33% |
| Operating Income | -26.93% | -78.10% | -95.02% | -2.21% | -47.64% |
| Income Before Tax | -38.03% | -46.48% | -120.75% | -58.22% | -66.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.03% | -46.48% | -120.75% | -58.22% | -66.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.03% | -46.48% | -120.75% | -58.22% | -66.04% |
| EBIT | -26.93% | -78.10% | -95.02% | -2.21% | -47.64% |
| EBITDA | -49.68% | -139.25% | -161.61% | -13.57% | -28.95% |
| EPS Basic | -14.29% | -22.64% | -90.00% | -51.61% | -66.67% |
| Normalized Basic EPS | -16.28% | -24.24% | -88.00% | -10.34% | -65.38% |
| EPS Diluted | -14.29% | -22.64% | -90.00% | -51.61% | -66.67% |
| Normalized Diluted EPS | -16.28% | -24.24% | -88.00% | -10.34% | -65.38% |
| Average Basic Shares Outstanding | 20.14% | 18.87% | 17.74% | 4.44% | 0.00% |
| Average Diluted Shares Outstanding | 20.14% | 18.87% | 17.74% | 4.44% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
